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INTRODUCTION
Cerebral  palsy  is  common,  affecting  about  2-3  per  1000 
children1.  These  children  may  have  a  motor  disorder 
characterised by spasticity, dystonia or both. This can result 
in significant difficulty with activities of daily living, pain and 
long term joint deformity2. There are a number of treatments 
available  for  the  management  of  spasticity  and  dystonia. 
This review will examine indications and practical issues for 
some of the common treatment options used in the paediatric 
population such as botulinum toxin and intrathecal baclofen 
and the newer therapy for dystonia management, deep brain 
stimulation.
Spasticity management in childhood cerebral palsy
A definition of spasticity was provided by Lance in 1980, 
‘Spasticity is a motor disorder characterized by a velocity-
dependent  increase  in  tonic  stretch  reflexes  (“muscle 
tone”) with exaggerated tendon jerks, resulting from hyper 
excitability of the stretch reflex, as one component of the 
upper motor neurone syndrome’.
Spasticity  results  from  a  lack  of  descending  impulses 
that  normally  stimulate  the  release  of  the  inhibitory 
neurotransmitter GABA which acts presynaptically to inhibit 
the release of excitatory neurotransmitters. Two of the most 
common causes of spasticity are cerebral palsy and acquired 
brain injury. Spasticity can result in functional problems with 
daily activities such as gait, feeding, washing and dressing. 
Over time it may result in joint contracture and hip dislocation 
in more severely affected individuals. It is recognised that a 
painful hip joint can result in poor tolerance of the seated 
position  and  may  result  in  the  need  for  frequent  turning 
at night. The discomfort and lack of sleep can exacerbate 
seizures,  dystonic  posturing  and  spasms,  the  child  can 
present as irritable and unsettled, in some the manifestations 
of  pain  include  teeth  grinding,  biting  and  head  banging. 
Identifying the source of pain and treating it can reduce the 
need  for  changes  in  anticonvulsants  and  tone  modifying 
agents. However spasticity can also be helping the child to 
maintain posture and function as underlying muscle strength 
may be low. Therefore it is important for any treatment to 
be titratable in order to maintain functional benefits whilst 
reducing spasticity.
Treatment options for spasticity 
Baclofen is a GABA agonist that is used to reduce muscle 
tone. Baclofen crosses the blood-brain barrier and binds at 
the GABA-B receptors of the laminae I-IV of the spinal cord, 
where primary sensory fibres end. It may be used for both oral 
and intrathecal administration. Baclofen can produce sedation 
when administered orally (that is, dose-related – table I); this 
may be minimized by initiating treatment at a low dose. This 
drug  may  also  cause  impairments  of  cognitive  functions, 
hypotonia and may lower the seizure threshold. Maintenance 
doses are titrated to individual need and the titration should 
be done slowly, ideally incremental increases should be three 
days apart.
INTRATHECAL BACLOFEN
Intrathecal baclofen is a treatment used in adults and children 
since the mid 1980’s. It can be considered in two groups: older 
ambulatory children or patients with severe spasticity in the 
upper and lower extremities. It has advantages in that it is 
titratable and reversible.
Mechanism
Intrathecal baclofen is delivered via an implantable pump. 
By infusing baclofen directly into the subarachnoid space 
around  the  spinal  cord,  potentiation  of  GABA-mediated 
inhibition of spasticity can be achieved while minimizing 
side effects secondary to high levels of baclofen in the brain. 
Intrathecal infusion of baclofen may be varied through the 
day to accommodate the patient’s activities3. Many studies 
have demonstrated that intrathecal baclofen therapy is useful 
in  the  management  of  spasticity  with  cerebral  palsy  and 
spinal origin4,5. In patients with spasticity of cerebral origin 
reduction in spasticity in the upper and lower extremities after 
six months of therapy has been reported5. ITB produces levels 
greater than four times the oral dose facilitating the use of 
much smaller doses for example 0.05-1.2mg per day
Patient management generally takes place in three phases: 
patient  selection,  patients  and  family  education,  and 
screening. 
Patient Selection
Clinically severe spasticity which impairs function in:
•	 Older ambulatory children © The Ulster Medical Society, 2009.
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•	 Patients  with  severe  spasticity  in  upper  and  lower 
extremities
•	 Patients with a combination of spasticity + dystonia
•	 Spinal injury
Ideally patients should have been tried on oral tone modifying 
medications first and have had some response to baclofen and 
no adverse reaction. 
Patient and family education
It is imperative that families have a clear understanding not 
only of the surgical procedure required but of the long term 
commitment in terms of pump maintenance and refilling. 
Patients should undergo functional assessments during the 
process of consideration for a baclofen pump. This facilitates 
a greater understanding of the level of ability and allows 
a  clearer  explanation  of  what  might  be  improved  using 
intrathecal baclofen. Local therapy teams can provide useful 
background information which assists the process. Written 
information should be provided explaining the assessment 
process,  surgical  procedure  and  follow  up  arrangements. 
Families and local teams should have access to protocols for 
emergency management. All of the information should be 
available in a child friendly format and accessible for young 
people with a learning disability. 
Baclofen screening trial
A dose of baclofen is delivered via an intra thecal bolus using 
the standard lumbar puncture technique. Generally a dose of 
50µg of baclofen is given in this intrathecal injection. The 
aim  is  to  observe  a  demonstrable  reduction  in  spasticity. 
There are a variety of techniques used in different centres to 
reliably assess this change in muscle tone, examples include 
a pre and post comparison of Ashworth scores, and change in 
range of hip abduction. It is important to explain to patients 
and families that the effect produced by the trial dose is not 
predictive of functional changes or the impact on upper limb 
tone which may be experienced following pump insertion.
Practical issues 
Insertion  of  the  baclofen  pump  is  undertaken  by  the 
neurosurgical  team.  The  procedure  for  insertion  of  an 
intrathecal baclofen pump lasts 1-1.5 hours. The pump is 
inserted under the covering of the abdominal muscles while 
the patient is under a general anaesthetic. A small catheter is 
inserted through a needle into the spinal fluid and is threaded 
upward  toward  the  neck. The  catheter  is  tunnelled  under 
the skin to the abdomen and is connected to the pump. The 
pump is filled with the drug baclofen and is programmed by 
a computer to continuously release a specified dose. Patients 
usually remain in hospital for five days after pump insertion. 
During that time, their baclofen dose is increased every day 
as needed. The pump needs to be refilled every two to six 
months,  depending  on  the  pump  size,  concentration  and 
dose. Refills are done using a syringe and needle and take 
approximately  thirty  minutes  to  complete.  At  that  time, 
baclofen doses are adjusted depending on the effects that 
are being seen. Doses typically increase slowly during the 
first year, and then remain at that level for years thereafter. 
The drug dose is not related to age or weight, and a gradual 
increase  during  the  first  six  to  nine  months  is  required. 
Generally, patients with ventriculoperitoneal shunts require 
lower doses. The battery in the pump lasts up to eight years 
at which time the pump needs to be replaced6.
Problems with baclofen pumps
Empty pump reservoir, catheter leaks or displacement, pump 
malfunction,  programming  error  and  refill  of  pump  with 
improper drug concentration are the possible mechanisms 
which  could  lead  to  an  ITB  withdrawal  syndrome  (table 
II) which can lead to muscle breakdown and multi system 
failure.  Management  includes  an  early  recognition  of 
syndrome,  proper  intensive  care  management,  high-dose 
benzodiazepines and prompt analysis of intrathecal pump 
with reinstitution of baclofen.
Outcomes following intrathecal baclofen therapy
Reduction  in  use  of  oral  medication  for  children  with 
spasticity has been described, with improvements in comfort 
and  function;  decreased  tone  and  spasms  also  observed5. 
Table I: 
Guide to the oral baclofen dose range in childhood:
1 month – 2 years 2 - 12 years 12 - 18 years Notes 
1-2mg 2mg 5mg Initial dose gradually increasing every three 
days
 > 1year
5mg
2-6 years 
10mg
6-12 years
15mg
20-30mg.  Max daily 
dose 100mg
Maintenance three times daily
Table II.
ITB withdrawal.
Clinical signs of ITB withdrawal
Increased spasticity
Agitation
Hallucinations
Severe itching
Hyperthermia
Seizures© The Ulster Medical Society, 2009.
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Some aspects of speech, communication, and saliva control 
seem  to  have  improved,  with  bowel  movement  frequency 
decreased in some children receiving intrathecal baclofen. 
Few  changes  in  feeding  and  nutritional  status  have  been 
reported. The majority of patients will sustain improved range 
of motion, decreased painful muscle spasm, and improvement 
in measures of independent function3-5. Finally, this treatment 
may be associated with possible complications, some studies 
suggest that children of younger age, as well as those with 
gastrostomy  tubes  and  non-ambulatory  status,  were  more 
likely to encounter complications necessitating removal of 
the pump such as pump pocket collections and infections7,8. 
Infection may remain isolated to the pump pocket or may 
track along the catheter, with consequent meningitis5.
Vloeberghs group demonstrated that ITB has a role in children 
with a combination of spasticity and dystonia. Interestingly 
they concluded that it was safe and effective to have both 
ITB  and  DBS  together  in  selected  patients  with  primary 
dystonias9. The American Academy  reviewed  all  the  trials 
for ITB available by 2000 and concluded that in a total of 
twenty-five  trials  seventeen  had  shown  clear  statistically 
significant improvements in areas such as moving and handling, 
pain, spasms, social participation and reducing the need for 
orthopaedic procedures. They commented that the other smaller 
trials had no power calculations therefore they could only be 
termed  inconclusive  rather  than  negative10.  Other  potential 
benefits that have been less extensively studied are benefits to 
sleep and respiratory function in patients with spasticity (table 
IV). One trial demonstrated significant improvements in these 
areas; however this clearly needs more investigation11.
BOTULINUM TOXIN THERAPY IN THE 
MANAGEMENT OF CHILDHOOD SPASTICITY 
Prior to the late 1990’s we were extremely limited in the focal 
medical management of movement disorders in children. A 
so called ‘birthday syndrome’ of almost annual Orthopaedic 
interventions overcame the functional difficulties associated 
with tightening at the ankle dorsiflexors, knee and hip flexors. 
In 1998 Botulinum Toxin type A became licensed for use in 
children over the age of two for management of dynamic 
equinus  foot  deformity  caused  by  spasticity  in  ambulant 
children with cerebral palsy. This remains the only on license 
indication, however there is a wide range of accepted ‘off 
license’ use for children, as outlined in summary documents 
such  as  the  European  Consensus  Statements.  Targeted 
injections to skeletal muscles (table V) in areas including the 
neck, upper limb, spine, hip and lower limb have been shown 
to reduce problems associated with increased muscle tone as 
part of the upper motor neurone syndrome12-15.
There are seven different naturally occurring serotypes of 
Botulinum Toxin, each acting at the nerve terminal end plate 
to block the release of Acetylcholine at the neuro-muscular 
junction, abolishing motor end plate potential. Botulinum 
Toxin type A (e.g. Botox, Dysport, Xeomin) has the widest 
international clinical use as it causes the longest duration of 
muscle relaxation. It is taken up into the end plate via the high 
affinity synaptic vesicle protein 2 (SV2) which is up regulated 
in active neurons. It then irreversibly stops exocytosis of 
Acetylcholine by targeting the SNAP-25 protein element of 
the synaptic vesicle release complex. This is clinically vital as 
active toxin works on active synapses, those muscles with over 
activation causing clinical problems are specifically targeted. 
The terminal end plate ceases to function and regresses over 
the next couple of months to the end of the axonal sheath. 
Resprouting then occurs from this point with the growth of 
a new neuro-muscular junction. This leads to the duration of 
action within the targeted nerve-muscle of between three to 
four months. Clinical gain is often seen for far longer than 
Table III.
ITB overdose.
Signs of ITB overdose
Excessive hypotonia
Drowsiness/reduced arousal
Respiratory depression requiring ventilation
Table IV . 
Benefits of ITB.
Positive results with Intrathecal baclofen
Reduced pain 
Improved QOL
Improved seating tolerance
Improved transfers
Ambulatory patients improving capacity to walk
Ease of care / level of support
Reduction in orthopaedic surgery
Table V .
Author centre uses of Botulinum Toxin type A in movement 
disorders
Area  Problems
Head and neck Sialorrhoea, Retro, lateral or rotatory 
torticollis
Shoulder Axillary hygiene, retraction, 
protraction, abduction, focal dystonia
Elbow Flexion, Extension
Wrist, thumb 
and hand
Flexion, hand hygiene/ 
hyperhydrosis, thumb adduction and 
flexion
Back Opisthotonus, extension, pain
Hip Pain secondary to spasm, flexion, 
adduction/scissoring, activities of 
daily living (toileting, dressing, 
changing), postural adaptation – 
comfort in sitting
Knee Pain, quadriceps spasticity, flexion, 
crouch/jump gait patterns
Ankle Equinus gait, inversion, pain
Foot, toe Claw toe, hitchhiker toe, dynamic toe 
and foot deformities© The Ulster Medical Society, 2009.
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this however with functional benefits lasting up to twelve to 
eighteen months16,17.
Different preparations have different pharmacokinetic and 
pharmacodynamic properties. Dose ranges are provided in 
Consensus documents and it is vital to remember to adhere to 
them as Botulinum Toxin type A is the most potent neurotoxin 
known to man. There is no direct correlation between doses 
of the preparations. Maximum doses of 12-14iu/kg of Botox 
or 25-30iu/kg of Dysport are recommended18.
The  core  of  successful  focal  or  global  management  in 
movement therapy is a multidisciplinary team assessment that 
works out functional goals for interventional therapy. Specific 
evaluation tools are necessary dependent on the possible site 
of intervention, the individual’s level of functional ability and 
age. A range of treatments are appropriate at different times of 
growth and development. As with Orthopaedic interventions 
it is important to consider a multi-level functional approach 
rather than injections to a single muscle body19.
Careful  explanation  of  effects  and  side  effects  of  the 
Botulinum Toxin injections should be given and informed 
written consent obtained. Rare local haematoma is the most 
common observed effect. There is no published report of 
localized infection or inflammation, though the authors have 
observed  this  twice  in  over  8,000  courses.  More  serious 
adverse events have been reported if dosing and/or dilution 
guidelines are not respected. These include excessive muscle 
weakness and local spread to other muscle groups. If the 
injections occur at the hip level then transient bowel or bladder 
incontinence has been observed, generally at the peak of effect 
one month following administration. There are two reported 
international fatalities over the last twelve years, potentially 
linked to Botulinum Toxin type A injections. Both of these 
had considerable confounding factors and though dilution and 
dosing guidelines were vastly exceeded in both cases neither 
had proven systemic spread of toxin on immunoassay of distal 
neuro-muscular junctions. 
The Botulinum Toxin injections should be administered by 
an experienced team in a child friendly setting. The injections 
themselves should take place with care to minimize trauma 
for the child and family. Local anaesthetic and inhaled or oral 
sedation or even general anaesthetic should be considered. 
It is generally accepted now that guidance beyond clinical 
palpation is needed for needle placement. In children the use 
of ultrasonography to localize muscles is widely used, though 
some centres use electrical stimulation or EMG. 
Re-evaluation is necessary at the peak of potential benefit 
and at the time of terminal re-sprouting. Botulinum Toxin 
injections are not a stand alone treatment modality and once 
again it should be stressed that it they are used as part of an 
integrated therapeutic approach in Paediatric Neurodisability. 
A post injection management programme is necessary. It may 
be necessary to repeat the course of injections and continuation 
or discontinuation as a therapeutic modality is dependent on 
functional gains, improved posture and/or improved comfort in 
the individual child. Secondary non-response due to muscular 
fibrosis or the formation of neutralizing antibodies against 
Botulinum Toxin A is rarely seen. When benefits are no longer 
observed  onward  referral  to  other  elements  of  movement 
therapy services may be necessary.
DYSTONIA IN CHILDREN WITH CEREBRAL 
PALSY
Dystonia is physiologically characterised by the involuntary 
co-contraction of agonist and antagonist muscle groups at a 
joint and an overflow flow into muscles or limbs not normally 
involved with intended movement, resulting in abnormalities 
in posture and twisting movements. Dyskinetic cerebral palsy 
has an estimated prevalence of 0.27 per 1000 live births20. 
In dystonia muscle tone typically fluctuates, varying from 
normal or low to extreme hypertonia.  It can be precipitated 
or worsened by attempts to move and can vary according to 
emotional state. Dystonia typically diminishes or disappears 
with distraction and sleep
There  are  numerous  systems  for  the  classification  of 
dystonia. Considering the underlying pathological process, 
dystonia  may  be  defined  as  (i)  Primary,  (ii)  Secondary 
or  (iii)  Heredodegenerative.  Primary  dystonias  are 
unaccompanied by other neurologic abnormalities, except 
tremor and occasionally myoclonus. Primary dystonias are 
often attributable to a genetic cause21. To date over 20 such 
dystonic  syndromes  have  been  identified,  with  mutations 
denoted  DYT21-24.  Secondary  dystonia  can  be  considered 
symptomatic, due to identifiable brain lesions or metabolic 
abnormalities.  Dyskinetic  cerebral  palsies  fall  into  this 
category. Dystonia may also be classified as focal, segmental 
or generalised depending upon the extent and distribution of 
muscle involvement.
The  basal  ganglia  have  long  been  implicated  in  the 
pathophysiology  of  dystonia25,26.  Considerable  evidence 
from electrophysiological studies in patients with primary 
dystonia suggests that abnormalities in the central nervous 
system are more widespread. These abnormalities include 
a loss of inhibition at various levels of the nervous system, 
abnormalities  in  sensory-motor  integration  and  abnormal 
neuroplasticity27. The basal ganglia connect to the cortex and 
thalamus and organize muscle-driven “motor” movements 
of the body. The major divisions of the basal ganglia are the 
caudate  nucleus,  putamen,  globus  pallidus  and  substantia 
nigra. The globus pallidus can be further divided into two 
subsections, the globus pallidus interna (GPi) and globus 
pallidus externa (GPe). Microelectrode recordings of GPi 
neurons taken during neurosurgical procedures on patients 
with primary and secondary dystonias have demonstrated 
low discharge rates, with irregular firing patterns6,28,29. Local 
field potentials recorded from the GPi have also demonstrated 
a prominent and abnormal oscillation in the 3-12 Hz band, 
synchronising with discharges from local neurons30. Further 
studies  have  demonstrated  correlation  between  these 
abnormal local field potential oscillations and oscillations 
in EMG recordings in dystonic patients31. This coupling is 
bi-directional, though the drive from the GPi to peripheral 
muscle outweighs that in the reverse direction32. Secondary 
Dystonia has been hypothesised as deriving from a reduced 
and disordered GPi output, with a pathological low frequency 
oscillation.
TREATMENT OF DYSTONIA
Treatment  options  in  dystonia  include  oral  medications, 
botulinum toxin for focal dystonia, intrathecal baclofen and 
neurosurgical interventions. In this latter category, surgical © The Ulster Medical Society, 2009.
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pallidotomy has been largely replaced with DBS to the GPi. 
Oral medications:
Numerous medications have been used in the management 
of  dystonia,  including  anti-cholinergic  medications  (e.g. 
trihexiphenidyl),  tetrabenazine,  benzodiazepines  (e.g. 
diazepam) and baclofen. 
Trihexyphenidyl  has  an  anticholinergic  effect,  reducing 
striated muscle contractions and parasympathetic activity. It 
has been widely used in the treatment of both primary and 
secondary dystonias for more then 20 years33. Retrospective 
data has suggested a beneficial effect in the management 
of dystonic cerebral palsy34. A more recent open-labelled 
study  in  children  with  CP  suggested  an  improvement  in 
arm function with its use35, though robust prospective data 
is lacking. A starting dose of 0.5 mg (infant), 1 mg (child) 
or 2 mg (adolescent) three times a day is generally used by 
the authors, increasing by 0.5, 1 or 2mg per day each week 
until either an effect is seen. In children and young adults 
doses can be increased until side effects occur or a total daily 
dose of 9, 30 or 90 mg is reached. The main side effects of 
trihexyphenidyl include dry eyes and mouth, gastrointestinal 
disturbances, urinary retention and behavioural disturbances. 
Pupil dilatation should not be considered a dose limiting 
side effect. These doses are in excess of the dose guidance 
in the British National Formulary. Use of these medications 
should only be considered in the context of ongoing specialist 
neurodisability follow up.
Tetrabenazine  is  a  benzoquinolone  that  depletes  synaptic 
dopamine transmission by a dual action, reducing vesicular 
monoamine  uptake  by  binding  to  vesicular  monoamine 
transporters, and also by acting as a post-synaptic dopamine 
receptor antagonist. Tetrabenazine is more widely used in 
the treatment of chorea in adult Huntington’s disease. Its use 
in children is less common, though a number of case reports 
have suggested efficacy. A retrospective study of 31 paediatric 
patients with hyperkinetic movement disorders refractory to 
other  medications  suggested  a  symptomatic  improvement 
in 24 (77%) patients36. In this study relatively high doses of 
tetrabenazine were required, over 100mg/day in three divided 
doses compared to an average of 70mg/day reported in adult 
studies.
Parkinsonism  is  recognised  as  a  common  side  effect  of 
tetrabenazine use in the adult population37. It is not possible 
to estimate the incidence in the paediatric population, but it 
has been hypothesised that this should be seen less frequently 
given the decline in dopamine function seen with age38.
DEEP BRAIN STIMULATION
In  recent  years  Deep  Brain  Stimulation  (DBS)39  has 
increasingly been used in the treatment of dystonia in both 
the paediatric and adult age group40-44. The technique utilises 
quadripolar electrodes implanted within the deep nuclei of 
the brain to deliver a continuous electrical signal. The GPi 
has become the established target in the treatment of dystonia 
(figure 1). The implanted electrodes are linked by an extension 
lead to a remote stimulator unit that is implanted in a similar 
fashion to a cardiac pacemaker into the subcutaneous tissue 
in  the  supraclavicular  region  or  the  abdomen.  This  unit 
may control either one or both of the implanted electrodes.   
Medtronic are currently the only manufacturer of approved 
devices. In paediatric patients, the contacts on the implanted 
electrodes are separated by 0.5 mm.
The  Complex  Motor  Disorder  Service  (CMDS)  at  the 
Evelina Children’s Hospital, London, in conjunction with the 
Functional Neurosurgery service at King’s College Hospital, 
London,  currently  provides  the  only  dedicated  paediatric 
DBS service in the UK. Patients with dystonia would be 
considered suitable for referral where conventional therapies 
(i.e. medications) do not adequately control symptoms or 
where side effects can not be tolerated by patients (figure 2).
Pre-Operative Assessment
Following  referral  to  the  CMDS,  patients  receive  a 
comprehensive baseline assessment by the multi-disciplinary 
therapy team. MRI of the brain allows detailed anatomical 
pictures  of  structures  of  interest,  which  is  useful  in 
determining diagnosis, location and extent of visible lesions, 
presence  of  co-morbidities  or  other  abnormalities.  This 
is  particularly  important  in  determining  whether  there  is 
an  intact  GPi  target  site  for  DBS. Transcranial  Magnetic 
Stimulation (TMS), also termed “Magstim” testing, is a non 
invasive and painless method of exciting neurons using strong 
magnetic fields held over the cortex. Electromyogram (EMG) 
recorded  over  hands  and  feet  are  used  to  measure  nerve 
conduction and velocity to ensure the corticospinal tract is 
Fig 1. Anatomical location of the Globus Pallidus Internus (GPi)
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intact.  Extensive corticospinal damage would be considered a 
relative contraindication to DBS. Such patients would instead 
be considered for ITB.
DBS Surgery
Pallidal DBS should be considered a reversible procedure, 
in contrast to the pallidotomy it has largely superseded. The 
implanted neurostimulator is often described as a brain “pace 
maker” (figure 3). The surgery is performed in awake adults, 
but in children a general anaesthetic is used. 
Mechanism and efficacy of DBS
The precise mechanism of action of DBS is far from clear. 
In  broad  terms,  stimulation  either  creates  a  “functional 
lesion” in the target nuclei or replaces an aberrant output 
from the target nuclei with a more physiological signal45-47. A 
functional lesioning mechanism would be consistent with the 
comparable effect of pallidal DBS and surgical pallidotomy.
Most studies of DBS in the treatment of dystonia have used 
the Burke-Fahn-Marsden Dystonia Rating scale as a measure 
of the severity of dystonic symptoms48. Primary dystonia is 
more responsive to Pallidal DBS then secondary dystonia49. 
In Secondary dystonia, improvements in BFMDRS compared 
to baseline of 5-40% have been reported. This contrasts with 
the up to 80% improvement seen in Primary dystonia. A 
minimum response of 25% is often defined as a “success”. It 
important to note that reduction in dystonia does not always 
equate  to  improvements  in  function,  but  quality  of  life, 
comfort and carer burden issues can be much improved both 
for the child and their carers.
The range of treatments available for children with motor 
disorders has  expanded  considerably  in  recent years. The 
best outcomes are obtained in the setting of an experienced 
multiprofessional team where children and families have the 
opportunity to learn about treatment options and have access 
to the right intervention at the right time. Treatment is more 
likely to be successful in the context of a child who is not in 
pain, has comfortable and appropriate equipment and is able 
to communicate.
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